



February 11, 2026

To,
The General Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001

COMPANY CODE : BAYERCROP
SCRIP CODE : 506285

Dear Sir / Madam,

Sub.: Unaudited Financial Results along with Limited Review Report of the Company for the quarter ended December 31, 2025, and Outcome of Board Meeting – February 11, 2026.

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at their meeting held today i.e., February 11, 2026, has inter alia, approved the Unaudited Financial Results of the Company for the quarter ended on December 31, 2025. We attach herewith a copy of the Unaudited Financial Results along with the Limited Review Report thereon from the Statutory Auditors, Deloitte Haskins & Sells LLP (ICAI Firm Registration No. 117366W/W-100018).

Further, please note that the Board Meeting commenced at 4.15 p.m. (IST) and concluded at 5.15 p.m. (IST).

We request you to take the same on record.

Thanking You.

Yours faithfully,
for **Bayer CropScience Limited**

Bharati Shetty
Company Secretary and Compliance Officer
(Membership No.: ACS 24199)

Bayer CropScience Ltd.
CIN: L24210MH1958PLC011173

Registered and Corporate Office:
Bayer House
Central Avenue
Hiranandani Estate
Thane (West) – 400 607
Maharashtra, India

Tel : +91 22 2531 1234
Fax : +91 22 2545 5063
www.bayer.in
www.cropscience.bayer.com

RESTRICTED

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF BAYER CROPSCIENCE LIMITED

1. We have reviewed the Statement of Unaudited Financial Results of BAYER CROPSCIENCE LIMITED ("the Company"), for the quarter and nine months ended December 31, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS LLP**

Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

Mohammed Bengali

(Partner)

Membership No. 105828

UDIN: 26105828YECYDM9054

Place: Mumbai

Date: February 11, 2026



BAYER CROPSCIENCE LIMITED

(Registered Office: Bayer House, Central Avenue, Hiranandani Estate, Thane - 400 607, CIN L24210MH1958PLC011173)

PART I						
STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025						
PARTICULARS	Quarter Ended			Nine Months Ended		Year Ended
	31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
Revenue from Operations	11,062	15,534	10,574	45,742	44,270	54,734
Other Income	159	138	322	484	826	1,197
Total Income	11,221	15,672	10,896	46,226	45,096	55,931
Expenses						
Cost of Materials Consumed	5,044	7,159	6,913	22,598	26,074	35,864
Purchases of Stock-in-Trade	230	1,021	288	1,881	1,308	1,530
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	1,011	2,036	(618)	3,727	965	(3,406)
Employee Benefits Expense	1,153	1,125	1,231	3,321	3,386	4,498
Finance Costs	52	44	37	143	113	170
Depreciation and Amortisation Expense	148	144	151	564	506	849
Other Expenses	2,453	2,140	2,558	7,507	7,349	9,352
Total Expenses	10,091	13,669	10,560	39,741	39,701	48,857
Profit Before Tax	1,130	2,003	336	6,485	5,395	7,074
Tax Expense/ (Credit)						
- Current Tax	165	469	20	1,214	1,164	1,514
- Deferred Tax	8	7	(26)	(-)*	(16)	(120)
Total Tax Expense	173	476	(6)	1,214	1,148	1,394
Profit for the period/ year	957	1,527	342	5,271	4,247	5,680
Other Comprehensive Income						
Items that will not be reclassified to profit or loss:						
- Remeasurement loss on Defined Benefit Plan	(39)	(7)	(9)	(52)	(14)	(69)
- Tax on remeasurement of Defined Benefit Plan	10	1	3	13	4	17
Total Other Comprehensive Income	(29)	(6)	(6)	(39)	(10)	(52)
Total Comprehensive Income for the period/ year	928	1,521	336	5,232	4,237	5,628
Paid up Equity Share Capital (Face Value ₹ 10/-)	449	449	449	449	449	449
Reserves (excluding Revaluation Reserve as per Balance Sheet)						28,055
Earnings per share (basic and diluted) (^ not annualised) in ₹	21.29^	33.98^	7.61^	117.28^	94.50^	126.38

* represents amount below the rounding off norm adopted by the Company.

NOTES:

1. The Company has only one reportable business segment, i.e. "Agri Care". The Company's business is seasonal in nature and hence quarterly figures are not necessarily representative of the full year's performance.
2. The Company does not have any subsidiary, joint venture, or associate company and consequently, the Company is not required to prepare consolidated financial results under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2025.
3. Pursuant to the notification issued by the Ministry of Labour and Employment, multiple central labour legislations have been consolidated into a unified framework comprising four Labour Codes becoming effective from November 21, 2025, collectively referred to as the 'New Labour Codes'. The Ministry of Labour and Employment published draft Central Rules and FAQs. The incremental impact arising from the New Labour Codes on employee benefit obligations, based on the available information as at the reporting date, is not material and has been accounted for in the financial results. The Company continues to monitor the finalization of Central and State Rules and will incorporate appropriate accounting treatment based on such developments.
4. The above results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on February 11, 2026. The above results have been subjected to limited review by the Statutory Auditors of the Company.



By Order of the Board

Vinit Jindal
Executive Director & Chief Financial Officer
DIN: 10849465

Place: Mumbai
Date: February 11, 2026

Handwritten signature